221 related articles for article (PubMed ID: 28973703)
1. Emerging Therapeutic Strategies in Breast Cancer.
Cox K; Alford B; Soliman H
South Med J; 2017 Oct; 110(10):632-637. PubMed ID: 28973703
[TBL] [Abstract][Full Text] [Related]
2. [Novel target therapies used in breast cancer management].
Semiglazova TIu; Semiglazov VV; Filatova LV; Gershanovich ML; Chudenko VA; Latipova DKh; Luk'ianchikova VS; Dashian GA; Paltuev RM
Vopr Onkol; 2011; 57(5):592-600. PubMed ID: 22238928
[No Abstract] [Full Text] [Related]
3. New directions for drug-resistant breast cancer: the CDK4/6 inhibitors.
Nichols M
Future Med Chem; 2015 Aug; 7(12):1473-81. PubMed ID: 26306734
[TBL] [Abstract][Full Text] [Related]
4. Advances in Targeted Therapies for Triple-Negative Breast Cancer.
McCann KE; Hurvitz SA; McAndrew N
Drugs; 2019 Jul; 79(11):1217-1230. PubMed ID: 31254268
[TBL] [Abstract][Full Text] [Related]
5. [New targeted therapies in breast cancer].
Coussy F; Teixeira L; Giacchetti S; Cuvier C; Hocini H; Espié M
Gynecol Obstet Fertil; 2014 Nov; 42(11):787-94. PubMed ID: 25442825
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
7. [New therapeutical strategies in metastatic hormone-dependent breast cancer].
Vilquin P; Cohen P; Maudelonde T; Tredan O; Treilleux I; Bachelot T; Heudel PE
Bull Cancer; 2015 Apr; 102(4):367-80. PubMed ID: 25799877
[TBL] [Abstract][Full Text] [Related]
8. Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer.
Lumachi F; Chiara GB; Foltran L; Basso SM
Cancer Genomics Proteomics; 2015; 12(6):385-90. PubMed ID: 26543084
[TBL] [Abstract][Full Text] [Related]
9. The Therapeutic Effects of Specific CDK4/6-inhibitors in Treating HR-positive, HER2-negative Advanced Breast Cancer.
Luis M
Klin Onkol; 2018; 31(4):305-308. PubMed ID: 30541316
[TBL] [Abstract][Full Text] [Related]
10. Molecular diagnostics for precision medicine in breast cancer treatment: what does the future hold?
Saji S; Kimura-Tsuchiya R; Sasaki E
Breast Cancer; 2016 Jan; 23(1):1-3. PubMed ID: 26534859
[No Abstract] [Full Text] [Related]
11. Advances in the treatment of advanced oestrogen-receptor-positive breast cancer.
Turner NC; Neven P; Loibl S; Andre F
Lancet; 2017 Jun; 389(10087):2403-2414. PubMed ID: 27939057
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cyclin-dependent kinases 4 and 6 in breast cancer.
Mayer EL
Clin Adv Hematol Oncol; 2015 Apr; 13(4):215-7. PubMed ID: 26352578
[No Abstract] [Full Text] [Related]
13. HER2-directed therapy: current treatment options for HER2-positive breast cancer.
Ahmed S; Sami A; Xiang J
Breast Cancer; 2015 Mar; 22(2):101-16. PubMed ID: 25634227
[TBL] [Abstract][Full Text] [Related]
14. [T-DM1 and pertuzumab: emerging anti-HER2 therapeutics].
Noguchi E; Shimizu C
Gan To Kagaku Ryoho; 2013 Jan; 40(1):10-4. PubMed ID: 23306913
[TBL] [Abstract][Full Text] [Related]
15. Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers.
Miranda F; Prazeres H; Mendes F; Martins D; Schmitt F
Mol Biol Rep; 2022 Jan; 49(1):717-733. PubMed ID: 34739691
[TBL] [Abstract][Full Text] [Related]
16. CDK4/6 Inhibitors for Advanced Hormone Receptor-Positive Breast Cancer, 2019 and Beyond.
Layman RM
J Natl Compr Canc Netw; 2019 Feb; 17(2):190-192. PubMed ID: 30787131
[No Abstract] [Full Text] [Related]
17. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
Kwapisz D
Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
[TBL] [Abstract][Full Text] [Related]
18. Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.
Tolba MF; Elghazaly H; Bousoik E; Elmazar MMA; Tolaney SM
Clin Transl Oncol; 2021 Oct; 23(10):1979-1994. PubMed ID: 33871826
[TBL] [Abstract][Full Text] [Related]
19. [Monoclonal antibody therapy in breast cancer].
Dank M; Tõkés T
Magy Onkol; 2013 Sep; 57(3):157-65. PubMed ID: 24107821
[TBL] [Abstract][Full Text] [Related]
20. Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies.
Fan W; Chang J; Fu P
Future Med Chem; 2015 Aug; 7(12):1511-9. PubMed ID: 26306654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
